UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 OPRX Nasdaq Capital Market FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Numb ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants William Febbo - CEO Ed Stelmakh - CFO Steve Silvestro - President Marion Odense-Ford - General Counsel Andrew D'Silva - SVP, Corporate Finance Conference Call Participants Ryan Daniels - William Blair Kyle Bauser - B. Riley Securities Max Michaelis - Lake Street Capital Anna Kruszenski - Barclays Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Second Quarter Fiscal 2 ...

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 128.57%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.11, delivering no surprise. Over the last four quarters, the company has ...

Exhibit 99.1 OptimizeRx Reports Second Quarter 2024 Financial Results - Q2 revenue of $18.8 million, increasing 36% year-over-year - Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62% - Won 8 DAAP deals during Q2 WALTHAM, Mass. – August 8, 2024 – OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the th ...

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. Date: Thursday, August 8, 2024 ...

Please call the conference telephone number or log on to the web access link five minutes prior to the start time. OptimizeRx provides trailblazing technology that fosters care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the healthcare journey. With the ability to synchronize messaging across 2 million healthcare providers and over 240 million adults across a multitude of digital channels including a proprietary point-of-care ne ...

WALTHAM, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its continued commitment to partnering with pharmaceutical brands to navigate the rapidly changing landscape of state-level consumer privacy legislation while executing comprehensive marketing programs nationwide. This month Florida, Oregon, and Tex ...

WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the results of an internal marketing study demonstrating that the Company's predictive marketing technology, the Dynamic Audience Activation Platform (DAAP), can deliver superior program results for life sciences brands looking to reach and engage ...

As routine diligence, OptimizeRx monitors performance of all client programs with which we are engaged so we can study outcomes and better understand performance impact on our clients' ability to measure return on marketing investment (ROI). In this instance, the study focused on a Major Depressive Disorder (MDD) therapy where a predictive targeting marketing campaign delivered nearly three times as many patients than the more traditional trigger-based marketing campaign. Enhanced Audience Quality: DAAP ide ...

• 84% of Patients Arrive at Doctor Visits Underinformed • Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies • OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client WALTHAM, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, announced ...